ArticleInternal medicine (Tokyo, Japan)2026
Refractory Systemic Lupus Erythematosus-associated Pericarditis Treated with Anifrolumab.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pericarditis in Systemic Lupus Erythematosus: A Comprehensive Review of Pathogenesis, Diagnosis, and Management.Cureus · 2026Review
- Pericarditis in Patients with Autoimmune Disease: Insights into Prevalence and Optimal Management.Methodist DeBakey cardiovascular journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 30-year-old woman with cutaneous lupus erythematosus, Kikuchi disease, and anti-ribonucleoprotein (RNP)/SS-A antibodies presented with fever and anterior chest pain. Initial echocardiography showed no pericardial effusion; however, follow-up revealed pericardial effusion, thus leading to a diagnosis of systemic lupus erythematosus (SLE)-associated acute pericarditis. Anti-RNP/SS-A antibodies are associated with serositis and elevated type I interferon (IFN) activity. Despite treatment with prednisolone, her condition persisted, thus prompting the administration of anifrolumab (300 mg), a monoclonal antibody that targets the type I IFN receptor. Following treatment, both pericardial effusion and the C-reactive protein levels promptly improved. This case highlights the fact that anifrolumab is a promising therapy for steroid-resistant SLE-associated pericarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.